Cellular pathology III Neoplasia : Introduction and Overview

1. Cellular pathology III • Neoplasia: Introduction and Overview

2. A neoplasia is a clonal proliferation of cells with somatic alterations and aberrant regulation of growth. • Non-threatening ones are benign. Malignant neoplasia are characterized by the abilities to invade adjacent tissue or metastasize to distant tissue.

3. A tumor is just a mass formed by a neoplasia. Pre-invasive (in situ) neoplasms don’t form tumors. • Though they share several key features, cancers are very heterogeneous.

4. Their common properties include dysregulated population growth, the abilities to invade and metastasize, the ability to modify the host environment, an extended doubling potential, and genomic instability.

5. Dysregulated population growth: Cancer cells typically ignore external signals regulating when to replicate, resulting in inappropriate replication. • Many known genetic defects (p53, cyclin D1, RB, Akt) in cancer affect genes related to growth factors and cell cycle regulation.

6. Despite this, not all cancers are completely autonomous to cell-growth regulation. • Usually, but not always, cancers have increased fractions of cells undergoing mitoses compared to normal cells.

7. Another contributing factor may be reduced cell death, often via resistance to apoptotic signals. • Common mutations in cancer also affect apoptosis genes (p53, Akt, Bax, Bcl2). So, in many cases, stopping cells from dividing inappropriately may fail to stop tumor growth.

8. In some cases, called, oncogene addiction, a cancer is highly dependent on one mutation, but this isn’t very common. • Growth factor (EGFR, Her2) signaling may also be altered.

9. Ability to invade and metastasize: Malignant neoplastic cells (cancer cells) can invade adjacent normal tissues and metastasize to distant sites. • Normal cells are confined to specific compartments, and require intercellular signals that indicate this for their survival.

10. With invasion, cell surface receptors for the native environment may be lost. E-cadherin (signaling, adhesion molecule) is commonly lost. • Many cancer cells also express new cell surface receptors allowing them to bind ECM components. • The tissue of origin loses some order and begins to remodel

11. Some malignant cells then secrete proteolytic enzymes • (matrix metalloproteinases, cathepsin D). Due to a lack of basement membrane, lymphatics are prone to invasion. Venules are likewise more frequently invaded, as they have less structure than arterioles. • Dense collagen and cartilage are quite resistant to invasion.

12. Metastasis occurs by lymphatics or blood. Cells must invade and survive the vascular environment, particularly its shear stress, apoptosis from the lack of solid matrix. • Some cancer cells have “stem like” properties such as small size that help them survive.

13. Malignant cells must also be able to adhere to and extravasate through the vascular walls. • The location is often determined by the drainage pattern, and lymph nodes are common sites of metastasis.

14. For tumor growth in a secondary site, the environment of a tissue must be somewhat suitable for that cancer cell’s properties (seed and soil hypothesis). • One important factor influencing this may be the chemokines present, kind of like how leukocytes figure out where to leave the bloodstream.

15. Modification of host environment: Tumors consist of stroma, inflammatory cells and vessels in addition to the cancer cells.

16. Many cancers produce angiogenic substances (VEGF, FGF), while others produce anti-angiogenic factors (endostatin, angiostatin). An anti-VEGF antibody (bevacizumab/avastin) has been used to treat some cancers.

17. Cancers are often sufficiently altered to elicit a cell-mediated immune response, and many have strategies to evade immune surveillance.

18. These include cytokines (TGF beta) or prostaglandin (PGE2) release, release of proteins that inhibit immune cells (IDO, ARG1), expression of decoy receptors, and secretion of decoy antigens.

19. Many cancers also secrete humoral factors like ectopic hormones (ACTH, PTH related protein) and cachexins (TNF). • They contribute to morbidity and mortality, but are poorly understood. They can result in paraneoplastic syndromes or cancer cachexia (wasting).

20. Extending doubling potential of tumor cells: Hayflick showed there to be limits to how long cells can replicate, which we now know is related to telomere length. • Most cancer cells express increased telomerase to maintain telomeres indefinitely; it’s normally only expressed in renewing cell populations.

21. Cancer cells still have shortened telomeres, likely because telomerase wasn’t activated until after telomeres had been shortened

22. Telomerase deficiency seems to lend itself toward chromosomal instability. • Assessing levels of telomerase could be useful in cancer diagnosis/detection, or even therapy though there is some activity in normal cells.

23. Genomic instability: Most cancer cells have abnormal chromosome number and structure, suggesting that they are continuously rearranged as tumor cells divide.

24. Shortened telomeres contribute to this, making chromosomes prone to breaks and rearrangements. • Inadequate mitotic spindle checkpoints , DNA damage checkpoints involving p53/BRCA that lead to translocations, and mismatch repair (increases mutation rate) also contribute

25. Microsatellites are particularly prone to mismatch repair errors, called microsatellite instability (MSI). • Genomic instability is likely part of the carcinogenesis process, or else it’s unlikely any one cell would accumulate so many mutations.

26. These changes also result in the morphologically abnormal nuclei we see in lab (hyperchomatism, abnormal/irregular nuclei). • Mitosis also looks abnormal in these cells. • This also allows cancers to rapidly mutate and acquire new properties like drug resistance.

27. Carcinogenesis, Cancer Development, and Growth of Cancers • Cancers arise from clonal evolution, meaning that sequential genetic changes are accompanied by clonal expansion of cells with a selective advantage for growth or survival.

28. This increases the changes of multiple mutations accumulating in any single cell. • The expansion is a non-genetic component of carcinogenesis. • When these altered cells divide (for extrinsic or intrinsic reasons), it’s called tumor promotion.

29. The steps of carcinogenesis are initiation (irreversible DNA alteration), promotion (stimulation of clonal expansion of that cell), and conversion to malignancy. • A genotoxin is something that induces mutation, both initiation and conversion. Human cancers require more than two mutations.

30. You can get chromosomal injury and pathologically atypical cells without invasion. These in situ cells may eventually become invasive and result in invasive/metastatic tumors. • From the first mutation to the clinical presentation, it may take 15-50 years to accumulate the mutations.

31. So there’s a long latency period between the cellular/genetic injury and development of the cancer to clinical significance.

32. Lesions with more nuclear atypia are called carcinoma in situ, whereas those with less nuclear atypia are called hyperplasias (technically a misuse of the term, since this is clonal). • Intermediate levels of atypia are called dysplasias.

33. Not all early neoplasms result in invasive cancers, but some are more likely than others (esp. higher grade ones). • Though cancers are ‘clonal’ in origin, they still have quite a bit or heterogeneity. • They all arise from a single precursor cell with some genetic changes common to all cancer cells.

34. But due to genetic instability, they develop more genetic changes over time, resulting in heterogeneity. • As the tumor evolves, one cell type generally predominates. • Most benign tumors don’t make it all the way to cancer.